158 related articles for article (PubMed ID: 33291419)
1. Large Scale Conversion of Trilobolide into the Payload of Mipsagargin: 8-
Zimmermann T; Drašar P; Rimpelová S; Christensen SB; Khripach VA; Jurášek M
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33291419
[TBL] [Abstract][Full Text] [Related]
2. Immunobiological properties of sesquiterpene lactones obtained by chemically transformed structural modifications of trilobolide.
Harmatha J; Vokáč K; Buděšínský M; Zídek Z; Kmoníčková E
Fitoterapia; 2015 Dec; 107():90-99. PubMed ID: 26474674
[TBL] [Abstract][Full Text] [Related]
3. Trilobolide and related sesquiterpene lactones from Laser trilobum possessing immunobiological properties.
Harmatha J; Buděšínský M; Vokáč K; Kostecká P; Kmoníčková E; Zídek Z
Fitoterapia; 2013 Sep; 89():157-66. PubMed ID: 23747321
[TBL] [Abstract][Full Text] [Related]
4. From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.
Christensen SB; Simonsen HT; Engedal N; Nissen P; Møller JV; Denmeade SR; Isaacs JT
Prog Chem Org Nat Prod; 2021; 115():59-114. PubMed ID: 33797641
[TBL] [Abstract][Full Text] [Related]
5. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
6. Immunoassay for determination of trilobolide.
Huml L; Jurášek M; Mikšátková P; Zimmermann T; Tomanová P; Buděšínský M; Rottnerová Z; Šimková M; Harmatha J; Kmoníčková E; Lapčík O; Drašar PB
Steroids; 2017 Jan; 117():105-111. PubMed ID: 27600788
[TBL] [Abstract][Full Text] [Related]
7. Trilobolide-porphyrin conjugates: on synthesis and biological effects evaluation.
Tomanová P; Rimpelová S; Jurášek M; Buděšínský M; Vejvodová L; Ruml T; Kmoníčková E; Drašar PB
Steroids; 2015 May; 97():8-12. PubMed ID: 25204594
[TBL] [Abstract][Full Text] [Related]
8. Trilobolide-steroid hybrids: Synthesis, cytotoxic and antimycobacterial activity.
Jurášek M; Džubák P; Rimpelová S; Sedlák D; Konečný P; Frydrych I; Gurská S; Hajdúch M; Bogdanová K; Kolář M; Müller T; Kmoníčková E; Ruml T; Harmatha J; Drašar PB
Steroids; 2017 Jan; 117():97-104. PubMed ID: 27543674
[TBL] [Abstract][Full Text] [Related]
9. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells.
Søhoel H; Jensen AM; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Olsen CE; Christensen SB
Bioorg Med Chem; 2006 Apr; 14(8):2810-5. PubMed ID: 16412648
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica.
Liu H; Jensen KG; Tran LM; Chen M; Zhai L; Olsen CE; Søhoel H; Denmeade SR; Isaacs JT; Christensen SB
Phytochemistry; 2006 Dec; 67(24):2651-8. PubMed ID: 17098264
[TBL] [Abstract][Full Text] [Related]
11. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.
Mahalingam D; Wilding G; Denmeade S; Sarantopoulas J; Cosgrove D; Cetnar J; Azad N; Bruce J; Kurman M; Allgood VE; Carducci M
Br J Cancer; 2016 Apr; 114(9):986-94. PubMed ID: 27115568
[TBL] [Abstract][Full Text] [Related]
12. Total synthesis of five thapsigargins: guaianolide natural products exhibiting sub-nanomolar SERCA inhibition.
Andrews SP; Ball M; Wierschem F; Cleator E; Oliver S; Högenauer K; Simic O; Antonello A; Hünger U; Smith MD; Ley SV
Chemistry; 2007; 13(20):5688-712. PubMed ID: 17508363
[TBL] [Abstract][Full Text] [Related]
13. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin.
Andrews SP; Tait MM; Ball M; Ley SV
Org Biomol Chem; 2007 May; 5(9):1427-36. PubMed ID: 17464412
[TBL] [Abstract][Full Text] [Related]
14. Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum Ca2+-ATPase with thapsigargin and thapsigargin analogs.
Winther AM; Liu H; Sonntag Y; Olesen C; le Maire M; Soehoel H; Olsen CE; Christensen SB; Nissen P; Møller JV
J Biol Chem; 2010 Sep; 285(37):28883-92. PubMed ID: 20551329
[TBL] [Abstract][Full Text] [Related]
15. Archangelolide: A sesquiterpene lactone with immunobiological potential from
Rimpelová S; Jurášek M; Peterková L; Bejček J; Spiwok V; Majdl M; Jirásko M; Buděšínský M; Harmatha J; Kmoníčková E; Drašar P; Ruml T
Beilstein J Org Chem; 2019; 15():1933-1944. PubMed ID: 31501660
[TBL] [Abstract][Full Text] [Related]
16. Sesquiterpene lactone trilobolide activates production of interferon-γ and nitric oxide.
Kmoníčková E; Harmatha J; Vokáč K; Kostecká P; Farghali H; Zídek Z
Fitoterapia; 2010 Dec; 81(8):1213-9. PubMed ID: 20727953
[TBL] [Abstract][Full Text] [Related]
17. Thapsigargin-From Traditional Medicine to Anticancer Drug.
Jaskulska A; Janecka AE; Gach-Janczak K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374919
[TBL] [Abstract][Full Text] [Related]
18. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.
Isaacs JT; Brennen WN; Christensen SB; Denmeade SR
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946547
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
[TBL] [Abstract][Full Text] [Related]
20. Structural modification of trilobolide for upgrading its immunobiological properties and reducing its cytotoxic action.
Harmatha J; Buděšínský M; Jurášek M; Zimmermann T; Drašar P; Zídek Z; Kmoníčková E; Vejvodová L
Fitoterapia; 2019 Apr; 134():88-95. PubMed ID: 30731148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
